MRVI (Maravai LifeSciences Holdings) Notes Receivable: $0.0 Mil (As of Mar. 2026)


MRVI Maravai LifeSciences Holdings Inc MRVI
62 GF Score
Price $6.15
GF Value $3.82
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Maravai LifeSciences Holdings Notes Receivable?

Maravai LifeSciences Holdings MRVI -1.44% 62 Notes Receivable is $0.0 Mil as of Mar. 2026. GuruFocus rates MRVI with a GF Score™ of 62/100 and a GF Value™ of $3.82 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Maravai LifeSciences Holdings's Notes Receivable for the quarter that ended in Mar. 2026 was $0.0 Mil.

Maravai LifeSciences Holdings Notes Receivable Related Terms

Maravai LifeSciences Holdings Notes Receivable Historical Data

* Premium members only.

The historical data trend for Maravai LifeSciences Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maravai LifeSciences Holdings Notes Receivable Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Maravai LifeSciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MRVI
62GF Score
Maravai LifeSciences Holdings Inc MRVI
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maravai LifeSciences Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.0 Mil mean?
Maravai LifeSciences Holdings (MRVI) has a Notes Receivable of $0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Maravai LifeSciences Holdings and its competitors.
Is Maravai LifeSciences Holdings' Notes Receivable too high?
Maravai LifeSciences Holdings' current Notes Receivable is $0.0 Mil. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Notes Receivable compare to LBRX and SLDB?
Maravai LifeSciences Holdings' Notes Receivable of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current Notes Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings (MRVI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.82, compared to a current price of $6.15 — trading 61% above its estimated fair value. The current Notes Receivable is $0.0 Mil. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MRVI), the current Notes Receivable is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?

Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued. The current stock price of $6.15 is trading 61% above its estimated GF Value™ of $3.82. GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.

Key valuation signals for MRVI:

  • Notes Receivable: $0.0 Mil
  • GF Value™: $3.82 vs. price of $6.15 (61% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maravai LifeSciences Holdings Business Description

Other Exchanges MAR:Germany
Address 10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score

Get the complete analysis for MRVI

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.15
Price
$3.82
GF Value